Literature DB >> 10952785

Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331.

S D Webley1, A Hardcastle, R D Ladner, A L Jackman, G W Aherne.   

Abstract

Uracil DNA misincorporation and misrepair of DNA have been recognized as important events accompanying thymidylate synthase (TS) inhibition. dUTPase catalyses the hydrolysis of dUTP to dUMP, thereby maintaining low intracellular dUTP. We have addressed the relationship between dUTPase expression and cellular sensitivity to TS inhibition in four human lung tumour cell lines. Sensitivity (5-day MTT assay) to the growth inhibitory effects of the non-polyglutamatable, specific quinazoline TS inhibitor ZD9331, varied up to 20-fold (IC(50)3-70 nM). TS protein expression correlated with TS activity (r(2)= 0.88, P = 0.05). Intracellular concentrations of drug following exposure to ZD9331 (1 microM, 24 h) varied by approximately 2-fold and dTTP pools decreased by > 80% in all cell lines. No clear associations across the cell lines between intracellular drug concentrations, TS activity/expression, or TTP depletion could be made. dUTPase activity varied 17-fold and correlated with dUTPase protein expression (r(2)= 0.94, P = 0.03). There was a striking variation in the amount of dUTP formed following exposure to ZD9331 (between 1.3 and 57 pmole 10(-6)cells) and was in general inversely associated with dUTPase activity. A large expansion in the dUTP pool was associated with increased sensitivity to a 24-h exposure to ZD9331 in A549 cells that have low dUTPase activity/expression. dUTPase expression and activity were elevated (approximately 3-fold) in two variants of a human lymphoblastoid cell line with acquired resistance to TS inhibitors, further suggesting an important role for this enzyme in TS inhibited cells. Copyright 2000 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10952785      PMCID: PMC2363540          DOI: 10.1054/bjoc.2000.1358

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  36 in total

1.  Enhancement of methotrexate cytotoxicity by uracil analogues that inhibit deoxyuridine triphosphate nucleotidohydrolase (dUTPase) activity.

Authors:  W R Beck; G E Wright; N J Nusbaum; J D Chang; E M Isselbacher
Journal:  Adv Exp Med Biol       Date:  1986       Impact factor: 2.622

2.  DNA glycosylases, endonucleases for apurinic/apyrimidinic sites, and base excision-repair.

Authors:  T Lindahl
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1979

3.  Purification and properties of the deoxyuridine triphosphate nucleotidohydrolase enzyme derived from HeLa S3 cells. Comparison to a distinct dUTP nucleotidohydrolase induced in herpes simplex virus-infected HeLa S3 cells.

Authors:  S J Caradonna; D M Adamkiewicz
Journal:  J Biol Chem       Date:  1984-05-10       Impact factor: 5.157

4.  Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole.

Authors:  N J Curtin; A L Harris; G W Aherne
Journal:  Cancer Res       Date:  1991-05-01       Impact factor: 12.701

5.  Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.

Authors:  B van Triest; H M Pinedo; Y van Hensbergen; K Smid; F Telleman; P S Schoenmakers; C L van der Wilt; J A van Laar; P Noordhuis; G Jansen; G J Peters
Journal:  Clin Cancer Res       Date:  1999-03       Impact factor: 12.531

6.  Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N-(4-(N-(( 2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino) benzoyl)-L-glutamic acid (CB3717), on human lymphoblastoid cells.

Authors:  R C Jackson; A L Jackman; A H Calvert
Journal:  Biochem Pharmacol       Date:  1983-12-15       Impact factor: 5.858

7.  Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer.

Authors:  Y Horio; T Takahashi; T Kuroishi; K Hibi; M Suyama; T Niimi; K Shimokata; K Yamakawa; Y Nakamura; R Ueda
Journal:  Cancer Res       Date:  1993-01-01       Impact factor: 12.701

8.  Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies.

Authors:  A L Jackman; D L Alison; A H Calvert; K R Harrap
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

9.  Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil.

Authors:  C P Spears; B G Gustavsson; M S Mitchell; D Spicer; M Berne; L Bernstein; P V Danenberg
Journal:  Cancer Res       Date:  1984-09       Impact factor: 12.701

10.  Human lymphoblastoid cells with acquired resistance to C2-desamino-C2-methyl-N10-propargyl-5,8-dideazafolic acid: a novel folate-based thymidylate synthase inhibitor.

Authors:  B M O'Connor; A L Jackman; P H Crossley; S E Freemantle; J Lunec; A H Calvert
Journal:  Cancer Res       Date:  1992-03-01       Impact factor: 12.701

View more
  14 in total

Review 1.  Uracil in DNA: consequences for carcinogenesis and chemotherapy.

Authors:  Sondra H Berger; Douglas L Pittman; Michael D Wyatt
Journal:  Biochem Pharmacol       Date:  2008-07-01       Impact factor: 5.858

2.  SMUG1 but not UNG DNA glycosylase contributes to the cellular response to recovery from 5-fluorouracil induced replication stress.

Authors:  Pratik Nagaria; David Svilar; Ashley R Brown; Xiao-Hong Wang; Robert W Sobol; Michael D Wyatt
Journal:  Mutat Res       Date:  2012-12-17       Impact factor: 2.433

3.  Novel opportunities for thymidylate metabolism as a therapeutic target.

Authors:  Peter M Wilson; William Fazzone; Melissa J LaBonte; Jinxia Deng; Nouri Neamati; Robert D Ladner
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

4.  Uracil incorporation into genomic DNA does not predict toxicity caused by chemotherapeutic inhibition of thymidylate synthase.

Authors:  Yuhong Luo; Mike Walla; Michael D Wyatt
Journal:  DNA Repair (Amst)       Date:  2007-10-17

5.  A novel fluorescence-based assay for the rapid detection and quantification of cellular deoxyribonucleoside triphosphates.

Authors:  Peter M Wilson; Melissa J Labonte; Jared Russell; Stan Louie; Andrew A Ghobrial; Robert D Ladner
Journal:  Nucleic Acids Res       Date:  2011-05-16       Impact factor: 16.971

6.  AP endonuclease deficiency results in extreme sensitivity to thymidine deprivation.

Authors:  Ken Dornfeld; Monika Johnson
Journal:  Nucleic Acids Res       Date:  2005-11-27       Impact factor: 16.971

7.  The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition.

Authors:  S D Webley; S J Welsh; A L Jackman; G W Aherne
Journal:  Br J Cancer       Date:  2001-08-03       Impact factor: 7.640

8.  dUTPase inhibition augments replication defects of 5-Fluorouracil.

Authors:  Anna Hagenkort; Cynthia B J Paulin; Matthieu Desroses; Antonio Sarno; Elisée Wiita; Oliver Mortusewicz; Tobias Koolmeister; Olga Loseva; Ann-Sofie Jemth; Ingrid Almlöf; Evert Homan; Thomas Lundbäck; Anna-Lena Gustavsson; Martin Scobie; Thomas Helleday
Journal:  Oncotarget       Date:  2017-04-04

9.  Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage.

Authors:  Peter M Wilson; William Fazzone; Melissa J LaBonte; Heinz-Josef Lenz; Robert D Ladner
Journal:  Nucleic Acids Res       Date:  2008-11-16       Impact factor: 16.971

Review 10.  Apoptosis and molecular targeting therapy in cancer.

Authors:  Mohamed Hassan; Hidemichi Watari; Ali AbuAlmaaty; Yusuke Ohba; Noriaki Sakuragi
Journal:  Biomed Res Int       Date:  2014-06-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.